ClinicalTrials.gg
CompletedNCT01923428Updated Apr 8, 2020Results posted

The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)

A Phase 2/3 interventional study of AZD1722 and Placebo in Constipation Predominant Irritable Bowel Syndrome, sponsored by Ardelyx. Completed at 4 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-04-08.

Sponsored by Ardelyx · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
356
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing tenapanor in Constipation — 3 open to participants now, 4 under way, 3 of them phase 3. tenapanor · Constipation.

Enrollment
4th of 11
356 · median 186
Started
2013
the only one that year
Phase 2/3
Only one
of the 11
Registered
2nd of 11
by date
Lead sponsor
9 of 11
Ardelyx

Among the 11 studies testing tenapanor in Constipation, this one is the 4th largest by enrollment, is the only one that started in 2013, is the only one in phase 2/3, and was the 2nd registered.

Constipation

1,047 studies on the registry are indexed under Constipation; 161 are open to participants now.

Browse Constipation studies →

Open to participants now

3 of the 11 studies testing tenapanor in Constipation are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About tenapanor

tenapanor: first FDA approval 2019 (IBSRELA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing tenapanor in Constipation, or all of them as a file.
02

Study summary

This phase 2, randomized, double blind, placebo-controlled, multi-center study will evaluate the safety and efficacy of three dose levels of AZD1722 in subjects with constipation predominant IBS (IBS-C) as defined by the ROME III criteria and who have active disease as determined during a two-week screening period. Subjects who qualify and are randomized into the study will receive 5, 20, or 50 mg of AZD1722 BID or placebo BID for 12 consecutive weeks. At the end of this treatment period, subjects will be followed for an additional 4 weeks.

03

Conditions studied

  • Constipation Predominant Irritable Bowel Syndrome
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females and males must agree to use appropriate methods of or be sterile (with appropriate documentation)
  • Subject is ambulatory
  • Subject meets definition of IBS-C using Rome III Criteria for the Diagnosis of IBS with a history of \<5 SBMs per week
  • Subject meets Screening eligibility criteria (see below)
  • A colonoscopy based on AGA guidelines; every 10 years at ≥ 50 years old, or the occurrence of any warning signs (i.e., unexplained weight loss, non-hemorrhoid blood in stools)
  • Ability to communicate well with the Investigator and to comply with the requirements of the entire study, including an understanding of how to use the touch-tone telephone electronic diary.
  • Written and a willingness to participate in the study as it is described.
  • Daily access to a touch tone telephone.

Exclusion criteria

Exclusion Criteria:

  • Functional diarrhea as defined by Rome III criteria
  • IBS with diarrhea (IBS-D), mixed IBS (IBS-M), or unsubtyped IBS as defined by Rome III criteria
  • Diagnosis or treatment of any clinically symptomatic biochemical or structural abnormality of the GI tract within 6 months prior to screening, or active disease within 6 months prior to screening. Including but not limited to cancer, inflammatory bowel disease, diverticulitis, duodenal ulcer, erosive esophagitis, gastric ulcer, pancreatitis (within 12 months of screening), cholelithiasis, amyloidosis, ileus, non-controlled GERD, gastrointestinal obstruction or carcinoid syndrome.
  • Use of medications that are known to affect stool consistency (Prohibited Medications), including fiber supplements, anti-diarrheals, cathartics, antacids, opiates, prokinetic drugs, laxatives, enemas, antibiotics within 4 weeks of enrollment, probiotics (including probiotic yogurt); or salt or electrolyte supplements containing sodium, potassium, chloride, or bicarbonate formulations during the seven days prior to treatment; unless specified as rescue medication, and used accordingly.
  • Clinical evidence of significant cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematologic, neurologic, psychiatric or any disease that may interfere with the subject successfully completing the trial.
  • The subject has a history or current evidence of laxative abuse (in the clinical judgment of the physician).
  • Hepatic dysfunction ( [SGPT] or AST [SGOT] >2.5 times the ) or renal impairment (serum creatinine > 2mg/dL).
  • Any evidence of or treatment of (other than localized basal cell, squamous cell skin cancer or cancer in situ that has been resected) within the previous year.
  • Any surgery on the stomach, small intestine or colon, excluding appendectomy.
  • Pregnant or lactating women.
  • A major psychiatric disorder (DSM-III-R or ) including major depression or other psychoses that has required hospitalization in the last 3 years. History of attempted suicide or uncontrolled bipolar disorder. Alcohol or substance abuse in the last year.
  • Participation in other clinical trials within 1 month prior to Day -14 (beginning of screening period).
  • If, in the opinion of the Investigator the subject is unable or unwilling to fulfill the requirements of the protocol or has a condition, which would render the results uninterpretable.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
356 participants (actual)

Study arms

  • Experimental
    5 mg BID

    AZD1722

    Drug: AZD1722

  • Experimental
    20 mg BID

    AZD1722

    Drug: AZD1722

  • Experimental
    50 mg BID

    AZD1722

    Drug: AZD1722

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Also known as: RDX5791, Tenapanor

  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. Percent Complete Spontaneous Bowel Movement Responders vs Placebo

    Weekly complete spontaneous bowel movement resaponders defined as an increase of one or more bowel movement per week from baseline for 6 of the 12 weeks

    Time frame: 12 weeks

07

Results

Posted Jan 10, 2020

Participant flow

Participant flow — Overall Study
Milestone5 mg BID20 mg BID50 mg BIDPlacebo
Started88898990
Completed69777880
Not completed19121110
Withdrew: Adverse event8633
Withdrew: Withdrawal by subject5304
Withdrew: Lost to follow-up2150
Withdrew: Protocol violation3021
Withdrew: Non compliance to treatment1201
Withdrew: Lack of efficacy0011

Outcome measures

PrimaryPercent Complete Spontaneous Bowel Movement Responders vs Placebo

Weekly complete spontaneous bowel movement resaponders defined as an increase of one or more bowel movement per week from baseline for 6 of the 12 weeks

Time frame:
12 weeks
Reported as:
Count of participants · Participants
Percent Complete Spontaneous Bowel Movement Responders vs Placebo
Participants5 mg BID20 mg BID50 mg BIDPlacebo
Percent Complete Spontaneous Bowel Movement Responders vs Placebo35385130
Statistical analysis
  • 50 mg BID · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 27

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
5 mg BID—2/88 (2.3%)10/88 (11.4%)
20 mg BID—1/89 (1.1%)13/89 (14.6%)
50 mg BID—0/89 (0%)15/89 (16.9%)
Placebo—1/90 (1.1%)4/90 (4.4%)
Most frequent serious events
Most frequent serious events
Event5 mg BID20 mg BID50 mg BIDPlacebo
Laryngeal neoplasmRespiratory, thoracic and mediastinal disorders1/880/890/890/90
Urinary Tract InfectionInfections and infestations1/880/890/890/90
small intestinal obstructionGastrointestinal disorders0/881/890/890/90
OsteomyelitisMusculoskeletal and connective tissue disorders0/880/890/891/90
Most frequent other events
Most frequent other events
Event5 mg BID20 mg BID50 mg BIDPlacebo
DiarrheaGastrointestinal disorders7/8811/8910/890/90
Urinary Tract InfectionInfections and infestations3/882/895/894/90

Baseline characteristics

Safety Analysis Set

Age, Categorical
Age, Categorical(Participants)5 mg BID20 mg BID50 mg BIDPlaceboTotal
<=18 years00000
Between 18 and 65 years84828481331
>=65 years475925
Sex: Female, Male
Sex: Female, Male(Participants)5 mg BID20 mg BID50 mg BIDPlaceboTotal
Female76777977309
Male1212101347
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)5 mg BID20 mg BID50 mg BIDPlaceboTotal
Hispanic or Latino22302429105
Not Hispanic or Latino66596561251
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)5 mg BID20 mg BID50 mg BIDPlaceboTotal
American Indian or Alaska Native00000
Asian03216
Native Hawaiian or Other Pacific Islander00000
Black or African American1819172276
White69676965270
More than one race10124
Unknown or Not Reported00000
BMI
BMI(kg/m^2)5 mg BID20 mg BID50 mg BIDPlaceboTotal
Mean29.5 ± 5.6528.5 ± 5.2728.3 ± 4.8728.7 ± 5.6328.7 ± 5.36
08

Study locations

4 sites
  • Boulder, Colorado, United States
  • Greensboro, North Carolina, United States
  • Winston-Salem, North Carolina, United States
  • Chattanooga, Tennessee, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2013, a primary completion of Oct 2014 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2020, 5 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2013
First posted
Aug 15, 2013
Start
Aug 2013
Primary completionActual
Oct 2014
CompletionActual
Oct 2014
Results first posted
Jan 10, 2020
Last update
Apr 8, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01923428
Lead sponsor
Ardelyx
Responsible party
Sponsor
First posted
Aug 15, 2013
Start date
Aug 2013
Primary completion
Oct 2014
Completion
Oct 2014
Results posted
Jan 10, 2020
Last update
Apr 8, 2020

Study contacts

David P Rosenbaum, Ph.D.
study director · Ardelyx, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenapanor

Start the discussion